Common questions about Feminax Ultra (FAQ)
Q: Why does Feminax Ultra specifically state it is for period pain relief?
The regulatory product license defines its primary purpose and indication. According to official product information, Feminax Ultra is specifically licensed for the relief of period pain (known medically as primary dysmenorrhoea). This positioning reflects the scope of its authorization by the national regulatory agency.
Q: How does the active ingredient in Feminax Ultra compare to ibuprofen or paracetamol?
The active ingredient, naproxen, is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID), which works to reduce pain by targeting and reducing inflammation. This mechanism differs from paracetamol (acetaminophen), which primarily acts on the central nervous system to block pain signals. Official regulatory sources define these different classifications.
Q: Is Feminax Ultra a different type of painkiller than a standard over-the-counter medicine?
Official documents classify Feminax Ultra as a Pharmacy (P) medicine in the UK regulatory framework. This means that while it is not a prescription-only drug, it is not available on general sale and must be purchased from a pharmacy under the supervision of a pharmacist.
Q: Is it typical to experience dizziness or drowsiness after taking Feminax Ultra?
Official regulatory documents for the active ingredient list both dizziness and drowsiness (feeling sleepy) as possible known side effects that may occur when using the medicine. If these effects are experienced, individuals should be aware of the impact on daily activities.
Q: Are there any long-term safety considerations for using Feminax Ultra occasionally?
The official product labeling stresses that this medicine is intended for short-term use. Regulatory guidelines universally emphasize the importance of using the lowest effective dose for the shortest possible duration to help mitigate the potential cardiovascular and gastrointestinal risks associated with the NSAID class of drugs.
Q: Why is the medicine recommended for use only on certain days of the menstrual cycle?
This medicine is classified for acute, short-term use, which aligns with the temporary nature of menstrual discomfort. Official administration guidelines mandate that the treatment course should be restricted to the length of the acute episode to ensure compliance with the principle of using the lowest effective dose for the shortest duration.
Q: Does taking Feminax Ultra with food or milk change how quickly it starts to work?
While official administration guidelines state that taking the product with food or milk is permitted, regulatory labeling also indicates that the presence of food may cause the medicine to take longer to start working. This is a factor related to the speed of absorption in the digestive system.
Q: What does it mean that Feminax Ultra is a 'gastro-resistant tablet'?
The term gastro-resistant means the tablet is covered in a special coating that prevents it from dissolving in the stomach's acid. This coating allows the tablet to pass into the small intestine before releasing the active ingredient, which is a design feature intended to reduce irritation to the lining of the stomach.
Q: Can Feminax Ultra be taken simultaneously with paracetamol or co-codamol?
Official regulatory warnings for both naproxen and paracetamol (acetaminophen) highlight separate safety considerations. While the combination is sometimes evaluated, there is a need for caution due to the risk of gastrointestinal side effects from naproxen and the potential for liver toxicity from paracetamol. Regulatory sources suggest caution when combining analgesics.
Q: Is there a known interaction between Feminax Ultra and oral contraceptives (birth control)?
Official regulatory documents and established interaction databases do not commonly list a direct interaction between naproxen and the effectiveness of oral contraceptives. However, due to the complexity of individual health profiles, official sources recommend consulting a healthcare provider for case-specific guidance on medication combinations.
Q: Is there a maximum age limit for using Feminax Ultra for period pain?
According to the official patient information, the product is specifically licensed as suitable for the relief of period pain in women aged 15 to 50 years. This age range is outlined in the dosage and eligibility section of the regulatory documents for this particular indication.
Q: Is Feminax Ultra described as suitable for women who are pregnant or planning a pregnancy?
Studies indicate that the active ingredient may make it harder to get pregnant, and use is generally not recommended when a person is actively trying to conceive. Furthermore, the official labeling states that the medicine is restricted or contraindicated (must not be used) from 20 weeks gestation onwards.
Q: Can men use Feminax Ultra for pain relief if the active ingredient is naproxen?
The specific branded product, Feminax Ultra, is licensed and indicated solely for the treatment of period pain in women. While the active component, naproxen, is used in other medicines to treat general inflammatory conditions in both men and women, this particular product's regulatory license is restricted to women's use for dysmenorrhoea.
Q: Where can I find the official patient information leaflet (PIL) for Feminax Ultra?
The official product documents, such as the Patient Information Leaflet (PIL) or the Summary of Product Characteristics (SmPC), can be found by searching the product name on the national regulatory agency's drug database for the country where the medicine was purchased. These databases host validated, authoritative documents.
Q: Does the medicine contain any ingredients that are common allergens?
Yes, the official regulatory labeling provides a complete list of inactive ingredients (excipients), which can include substances like soya oil/lecithin or specific coloring agents that may be common allergens. Official product information advises that patients with known allergies consult the Patient Information Leaflet (PIL) for the full ingredient list.
Q: What should a user do if they miss a scheduled time for taking the medicine?
Official administration guidelines state that if a dose is forgotten, it should be taken as soon as it is remembered, unless it is nearly time for the next dose. In that case, the missed dose should be skipped entirely. Regulatory sources state that a double dose should not be taken to compensate for a missed one.
Q: Is there a risk of developing a dependency on Feminax Ultra?
The active ingredient, naproxen, belongs to the class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Official classification and medical guidance confirm that it is not considered an addictive medication or a narcotic, and there is no documented risk of physical or psychological dependence.
Q: Are there non-period related conditions where the active ingredient is used for inflammation?
The active ingredient, Naproxen, is officially indicated in other medicinal products for a range of inflammatory and pain conditions beyond dysmenorrhoea. These include, but are not limited to, rheumatoid arthritis, osteoarthritis, acute flares of gout, and soft tissue injuries like tendinitis or bursitis.
Q: Are headaches or confusion listed as possible effects in the official safety information?
Official regulatory safety information lists headache as a common adverse event associated with the active ingredient. While less common, confusion is also listed as a possible adverse reaction, which can sometimes be a sign of a more serious, though rare, neurological or systemic reaction.